This is an investigational study. Bevacizumab, carboplatin, and paclitaxel are each FDA approved and commercially available for the treatment of many types of cancer. The combination of carboplatin and paclitaxel is FDA approved and commercially available for the treatment of epithelial ovarian, primary peritoneal, or fallopian tube cancer. At this time, the addition of bevacizumab to the combination of carboplatin and paclitaxel is not FDA approved and is being used in research only.